Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer

被引:67
作者
Masuda, N
Matsui, K
Negoro, S
Takifuji, N
Takeda, K
Yana, T
Kobayashi, M
Hirashima, T
Kusunoki, Y
Ushijima, S
Kawase, I
Tada, T
Sawaguchi, H
Fukuoka, M
机构
[1] Osaka Prefectural Habikino Hosp, Dept Internal Med, Osaka 583, Japan
[2] Osaka Prefectural Habikino Hosp, Dept Radiol, Osaka 583, Japan
[3] Kinki Univ, Sch Med, Dept Internal Med 4, Osaka 589, Japan
[4] Osaka City Gen Hosp, Dept Resp Dis, Osaka, Japan
关键词
D O I
10.1200/JCO.1998.16.10.3329
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine the response rate, survival and toxicity of irinotecan (CPT-11), a topoisomerase I inhibitor, combined with etoposide, a topoisomerase II inhibitor, in refractory or relapsed small-cell lung cancer (SCLC). Patients and Methods: Twenty-five patients with refractory or relapsed SCLC were entered onto the trial. All 25 patients had been pretreated with some form of cisplatin-based combination chemotherapy and had also received previous etoposide- or anthracycline-containing chemotherapy. The median time off chemotherapy was 6.7 months (range, 0.9 to 23.5). Patients were treated at 4-week intervals using CPT-11 (9 starting dose of 70 mg/m(2) intravenously on days 1, 8, and 15) plus etoposide (80 mg/m(2) intravenously on days 1 to 3), with a subsequent dose based on toxicity In addition, recombinant human granulocyte colony-stimulating factor (rhG-CSF; 2 mu g/kg/d) was given from day 4 to day 21, except on the days of CPT-I 1 administration. Results: All patients were assessable for toxicity and survival. Twenty-four patients were assessable for response. There were 14 partial responses (PRs) and three complete responses (CRs), for an overall response rate of 71% (95% confidence interval, 53% to 89%). The median response duration was 4.6 months. Median survival was 271 days. Major toxicities were myelosuppression (predominantly leukopenia) and diarrhea. Grade 3 to 4 neutropenia and thrombocytopenia occurred in 56% and 20% of patients, respectively. Grade 3 to 4 diarrhea was observed in 4%. There was one treatment-related death due to severe myelosuppression. Conclusion: A combination of CPT-11 and etopaside with rhG-CSF support is an active therapy against refractory or relapsed SCLC and deserves to be studied more extensively in a phase III trial. (C) 1998 by American Society of Clinical Oncology.
引用
收藏
页码:3329 / 3334
页数:6
相关论文
共 34 条
[21]   A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer [J].
Masuda, N ;
Fukuoka, M ;
Fujita, A ;
Kurita, Y ;
Tsuchiya, S ;
Nagao, K ;
Negoro, S ;
Nishikawa, H ;
Katakami, N ;
Nakagawa, K ;
Niitani, H .
BRITISH JOURNAL OF CANCER, 1998, 78 (02) :251-256
[22]  
MASUDA N, 1990, CANCER, V65, P2635, DOI 10.1002/1097-0142(19900615)65:12<2635::AID-CNCR2820651206>3.0.CO
[23]  
2-J
[24]   Irinotecan (CPT-11): Pharmacology and clinical applications [J].
Masuda, N ;
Kudoh, S ;
Fukuoka, M .
CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, 1996, 24 (01) :3-26
[25]   CPT-11 - A NEW DERIVATIVE OF CAMPTOTHECIN FOR THE TREATMENT OF REFRACTORY OR RELAPSED SMALL-CELL LUNG-CANCER [J].
MASUDA, N ;
FUKUOKA, M ;
KUSUNOKI, Y ;
MATSUI, K ;
TAKIFUJI, N ;
KUDOH, S ;
NEGORO, S ;
NISHIOKA, M ;
NAKAGAWA, K ;
TAKADA, M .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (08) :1225-1229
[26]   SMALL CELL LUNG-CANCER 1973-1983 - EARLY PROGRESS AND RECENT OBSTACLES [J].
MORSTYN, G ;
IHDE, DC ;
LICHTER, AS ;
BUNN, PA ;
CARNEY, DN ;
GLATSTEIN, E ;
MINNA, JD .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1984, 10 (04) :515-539
[27]   Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer [J].
Oshita, F ;
Noda, K ;
Nishiwaki, Y ;
Fujita, A ;
Kurita, Y ;
Nakabayashi, T ;
Tobise, K ;
Abe, S ;
Suzuki, S ;
Hayashi, I ;
Kawakami, Y ;
Matsuda, T ;
Tsuchiya, S ;
Takahashi, S ;
Tamura, T ;
Saijo, N .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) :304-309
[28]  
PORTER LL, 1985, CANCER TREAT REP, V69, P479
[29]  
SUGIMOTO Y, 1990, CANCER RES, V50, P7962
[30]  
SUGIURA T, 1989, Proceedings of the American Association for Cancer Research Annual Meeting, V30, P408